Featured Story | By Nick Paul Taylor Numab Therapeutics has raised CHF 100 million ($111 million) to expand clinical development of its lead PD-L1x4-1BB drug candidate into multiple cancer indications. Novo Ventures and HBM Partners co-lead the series C round with assists from investors on both sides of the Atlantic. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Iovance Biotherapeutics CEO Maria Fardis will exit the company after the company said on Tuesday that the FDA requested more potency assay data for lifileucel, its lead candidate. read more By Amirah Al Idrus Bristol Myers Squibb is no stranger to mixing checkpoint inhibitors—see the many indications in development for the combination of Opdivo and Yervoy. Now, the drugmaker is one step closer to offering a new checkpoint inhibitor cocktail for the treatment of advanced melanoma, with the first phase 3 data for a LAG-3 antibody in tandem with the PD-1 blocker Opdivo. read more By Nick Paul Taylor Eli Lilly has completed a fifth global registration study of tirzepatide, teeing it up to seek approval of the dual GIP/GLP-1 agonist by the end of the year. All three doses of tirzepatide bettered the blood glucose reduction and weight loss seen in the insulin glargine arm of the latest phase 3 trial. read more By Ben Adams Battered and bruised by a tough journey, the Voyager 1 space probe is exiting our Solar System into worlds unknown; now, those running its earthly biotech namesake are taking a similar same path. read more By Kyle LaHucik Haya Therapeutics, a Swiss precision medicine biotech, came out of stealth today with nearly $20 million in seed funding for anti-fibrotic therapies targeting emerging field of long non-coding RNAs read more By Amirah Al Idrus PD-1 inhibitors work well in about one-fifth of patients with colorectal cancer, but the other 80% are not so lucky. Their tumors are immunologically “cold,” meaning they don’t respond to immunotherapies like Merck’s Keytruda. Enter favezelimab, Merck’s LAG-3-targeting antibody, which helped Keytruda make a dent in metastatic colorectal cancer in very sick patients in a phase 1 study. read more By Amirah Al Idrus CAR-T and other cell therapies have seen success in blood cancers but have shown limited effect in solid tumors. Adaptimmune is taking an engineered T-cell receptor approach to change that and its first phase 2 data, from patients with rare soft-tissue sarcomas, look promising. The MAGE-A4-targeting treatment, afamitresgene autolecel, shrank tumors in 39.3% of the patients. read more By Conor Hale Where there’s smoke there’s fire, and hot on the heels of closing more than a half-billion dollars in venture capital funding, Exscientia announced a drug discovery deal with Bristol Myers Squibb that could pay out up to $1.2 billion or more. The contract starts with $50 million upfront, plus $125 million for near-term successes, before milestones escalate into the 10-figure range. read more By Angus Liu Recent research suggests that microorganisms living in the human gut may play a role in diseases ranging from obesity to cancer. A team at Harvard Medical School has gone one step further, linking the microbiome’s genetic features to multiple diseases. read more By Arlene Weintraub Researchers at the University of Texas MD Anderson Cancer Center led the development of a GLS1 inhibitor that is now showing promise in patients with a variety of solid tumor types. Among the patients who had the longest responses in a phase 1 study were people with ovarian cancer and melanoma that was resistant to checkpoint inhibitors. read more |  | LabConnect is the leader in innovative central laboratory services for cell and gene therapies. Far more than typical central laboratory support, only LabConnect offers comprehensive, specialized services customizable to meet the unique needs of your complex clinical trials. Connect with us today. |
Resources Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
.jpg)
